Guoqi Teng1, Xiang Zhao1, James P Lees-Miller1, Darrell Belke1, Chunhua Shi1, Yongxiang Chen1, Edward R O'Brien1, Paul W Fedak1, Nathan Bracey1, James C Cross1, Henry J Duff2. 1. From the Libin Cardiovascular Institute, Faculty of Medicine (G.T., J.P.L.-M., D.B., C.S., Y.C., E.R.O'B., P.W.F., N.B., H.J.D.) and Department of Comparative Biology and Experimental Medicine and Faculty of Veterinary Medicine (X.Z., J.C.C.), University of Calgary, Calgary, Alberta, Canada. 2. From the Libin Cardiovascular Institute, Faculty of Medicine (G.T., J.P.L.-M., D.B., C.S., Y.C., E.R.O'B., P.W.F., N.B., H.J.D.) and Department of Comparative Biology and Experimental Medicine and Faculty of Veterinary Medicine (X.Z., J.C.C.), University of Calgary, Calgary, Alberta, Canada. hduff@ucalgary.ca.
Abstract
BACKGROUND: N629D KCNH2 is a human missense long-QT2 mutation. Previously, we reported that the N629D/N629D mutation embryos disrupted cardiac looping, right ventricle development, and ablated IKr activity at E9.5. The present study evaluates the role of KCNH2 in vasculogenesis. METHODS AND RESULTS: N629D/N629D yolk sac vessels and aorta consist of sinusoids without normal arborization. Isolated E9.5 +/+ first branchial arches showed normal outgrowth of mouse ERG-positive/α-smooth muscle actin coimmunolocalized cells; however, outgrowth was grossly reduced in N629D/N629D. N629D/N629D aortas showed fewer α-smooth muscle actin positive cells that were not coimmunolocalized with mouse ERG cells. Transforming growth factor-β treatment of isolated N629D/N629D embryoid bodies partially rescued this phenotype. Cultured N629D/N629D embryos recapitulate the same cardiovascular phenotypes as seen in vivo. Transforming growth factor-β treatment significantly rescued these embryonic phenotypes. Both in vivo and in vitro, dofetilide treatment, over a narrow window of time, entirely recapitulated the N629D/N629D fetal phenotypes. Exogenous transforming growth factor-β treatment also rescued the dofetilide-induced phenotype toward normal. CONCLUSIONS: Loss of function of KCNH2 mutations results in defects in cardiogenesis and vasculogenesis. Because many medications inadvertently block the KCNH2 potassium current, these novel findings seem to have clinical relevance.
BACKGROUND:N629DKCNH2 is a human missense long-QT2 mutation. Previously, we reported that the N629D/N629D mutation embryos disrupted cardiac looping, right ventricle development, and ablated IKr activity at E9.5. The present study evaluates the role of KCNH2 in vasculogenesis. METHODS AND RESULTS:N629D/N629D yolk sac vessels and aorta consist of sinusoids without normal arborization. Isolated E9.5 +/+ first branchial arches showed normal outgrowth of mouse ERG-positive/α-smooth muscle actin coimmunolocalized cells; however, outgrowth was grossly reduced in N629D/N629D. N629D/N629D aortas showed fewer α-smooth muscle actin positive cells that were not coimmunolocalized with mouse ERG cells. Transforming growth factor-β treatment of isolated N629D/N629D embryoid bodies partially rescued this phenotype. Cultured N629D/N629D embryos recapitulate the same cardiovascular phenotypes as seen in vivo. Transforming growth factor-β treatment significantly rescued these embryonic phenotypes. Both in vivo and in vitro, dofetilide treatment, over a narrow window of time, entirely recapitulated the N629D/N629D fetal phenotypes. Exogenous transforming growth factor-β treatment also rescued the dofetilide-induced phenotype toward normal. CONCLUSIONS: Loss of function of KCNH2 mutations results in defects in cardiogenesis and vasculogenesis. Because many medications inadvertently block the KCNH2 potassium current, these novel findings seem to have clinical relevance.
Authors: F Extramiana; O Milleron; S Elbitar; A Uccellini; M Langeois; M Spentchian; G Delorme; F Arnoult; I Denjoy; C Bouleti; V Fressart; F Iserin; P Maison-Blanche; M Abifadel; A Leenhardt; C Boileau; G Jondeau Journal: Sci Rep Date: 2018-08-29 Impact factor: 4.379